Magenta Therapeutics Inc (NASDAQ:MGTA) insider Michael P. Cooke sold 7,500 shares of the company’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $13.00, for a total value of $97,500.00. Following the completion of the transaction, the insider now directly owns 244,396 shares of the company’s stock, valued at approximately $3,177,148. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of Magenta Therapeutics stock opened at $12.44 on Tuesday. The stock has a 50 day moving average of $10.87 and a 200 day moving average of $12.29. Magenta Therapeutics Inc has a 12 month low of $5.31 and a 12 month high of $21.00. The firm has a market cap of $516.22 million, a PE ratio of -3.97 and a beta of 3.24.
Magenta Therapeutics (NASDAQ:MGTA) last announced its quarterly earnings results on Wednesday, November 13th. The company reported ($0.54) EPS for the quarter, meeting analysts’ consensus estimates of ($0.54). On average, sell-side analysts predict that Magenta Therapeutics Inc will post -2.01 earnings per share for the current year.
A number of research firms have recently weighed in on MGTA. Zacks Investment Research lowered Magenta Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, October 15th. ValuEngine lowered Magenta Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, November 20th. Finally, Cowen reaffirmed a “buy” rating on shares of Magenta Therapeutics in a research note on Wednesday, November 13th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $16.33.
Magenta Therapeutics Company Profile
Magenta Therapeutics, Inc, a clinical-stage biotechnology company, develops novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a novel stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an antibody-drug conjugate program to prevent acute graft and host diseases.
See Also: Systematic Risk and Investors
Receive News & Ratings for Magenta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magenta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.